Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 06 2023
30 06 2023
Historique:
received:
17
01
2023
accepted:
29
06
2023
medline:
3
7
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Liver resection (LR) is the only recommended effective curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis of patients with ICC is still poor even after curative resection. Recently, many researchers focused on the therapeutic value of LT for patients with ICC. This study aimed to identify the role of liver transplantation in patients with ICC by internally comparing with LR in ICC and externally comparing with LT in HCC. We obtained patient data from SEER database. Propensity score methods were applied to control confounders. Survival outcome was estimated using Kaplan-Meier survival curves and compared using the log-rank test. A total of 2538 patients with ICC after surgery and 5048 patients with HCC after LT between 2000 and 2019 were included in this study. The prognosis of patients with ICC after LT were better than patients with ICC after LR in both unmatched (HR 0.65, P = 0.002) and matched cohorts (HR 0.62, P = 0.009). The 5-year OS rate after LT could be improved to 61.7% in patients with local advanced ICC after neoadjuvant chemotherapy. In conclusion, our study demonstrated that the prognosis of patients with ICC after LT was better than patients with ICC after LR, but was still worse than patients with HCC after LT. LT with neoadjuvant chemotherapy should be considered as a treatment option for patients with locally advanced ICC, but more prospective multicenter clinical trials are needed to further confirm these results.
Identifiants
pubmed: 37391482
doi: 10.1038/s41598-023-37896-2
pii: 10.1038/s41598-023-37896-2
pmc: PMC10313647
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10630Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
J Am Coll Surg. 2009 Jan;208(1):134-47
pubmed: 19228515
J Hepatol. 2004 Mar;40(3):472-7
pubmed: 15123362
Front Oncol. 2022 Jan 21;11:841694
pubmed: 35127541
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
Ann Surg Oncol. 2008 Feb;15(2):600-8
pubmed: 17987347
Curr Oncol Rep. 2017 Jul;19(7):50
pubmed: 28656502
Hepatology. 2016 Oct;64(4):1178-88
pubmed: 27481548
Lancet. 2014 Sep 27;384(9949):1182-3
pubmed: 25263671
J Surg Oncol. 2021 Oct;124(5):906-907
pubmed: 34120341
Hepatology. 2022 Feb;75(2):455-472
pubmed: 34859465
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Hepatology. 2001 Jun;33(6):1353-7
pubmed: 11391522
J Hepatol. 2012;56 Suppl 1:S75-87
pubmed: 22300468
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Lancet Oncol. 2012 Jan;13(1):e11-22
pubmed: 22047762
Liver Transpl. 2011 Oct;17 Suppl 2:S44-57
pubmed: 21695773
Gastroenterology. 2009 Apr;136(4):1134-44
pubmed: 19245868
Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348
pubmed: 29548617
JAMA Surg. 2014 May;149(5):432-8
pubmed: 24599477
Am J Transplant. 2022 Mar;22(3):823-832
pubmed: 34856069